About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed
LOGIN


Sign up to stay informed--receive email notifications for this journal

BioResearch Open Access

Editor-in-Chief: Robert Lanza, MD

Online ISSN: 2164-7860 • Published Bimonthly

Current Volume: 3

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Manuscripts must be submitted online using the following url:

    http://mc.manuscriptcentral.com/biores


    BioResearch Open Access provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.  Reports describing the results of basic research, technical advances, and clinical studies are within the scope of BioResearch Open Access.

    OPEN ACCESS POLICY FOR BIORESEARCH OPEN ACCESS

    BioResearch Open Access has an article processing fee of $1,700USD for the first accepted article and $1,400USD for any subsequent accepted articles.  There is no charge for color artwork. All articles in the Journal will be deposited upon publication, without embargo, to PubMedCentral at the U.S. National Library of Medicine  (Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.)  BioResearch Open Access is fully NIH-, HHMI-, and Wellcome Trust-compliant.  Your article will be free online at www.liebertpub.com/biores, and will be easily searchable on Google, Google Scholar, and other search engines.  For further details on our open access policy go to: http://www.liebertpub.com/lpages/bioresearch-open-access/18/

    The Journal will publish basic science and translational research in the form of the following article types:

    Original Research Articles are full-length descriptions of original research in all fields of scientific, technical, and biomedical research. The investigation may focus on basic science, clinical outcomes, or applications.  Word limit: 3,000 words excluding references, figures, and tables with an abstract of 350 words or less.

    Comprehensive Reviews are appraisals of research and clinical trials in fields of current interest. While these are subject to the same review process as other papers, authors are encouraged to speculate about future promise of new procedures and techniques. Unsolicited reviews are welcome. Word limit:  5,000 words excluding references, figures, and tables with an abstract of 350 words or less.

    Mini-reviews are brief summaries of developments in fast-moving areas of biomedical research, and must be must be based on published articles. Mini-reviews must not exceed 2,500 words excluding references, figures, and tables and should contain an abstract of 300 words or less.

    Rapid Communications are intended for the accelerated publication of cutting-edge, groundbreaking biomedical findings, and should be no more than 1,500 words excluding references with no more than two figures or tables.  An abstract of 200 words or less is required.

    Brief Reports are descriptions of completed findings that have met the criteria of biomedical research and peer review, but do not qualify as full original paper.  These reports should be no more than 1,500 words excluding references, with no more than two figures or tables and should contain an abstract of 250 words or less.

    Technical  Reports briefly and succinctly describe improvements or helpful modifications in current procedures.  Word limit:  2,000 words excluding references, figures, and tables.  Abstract not required.

    Hypothesis Articles:  Original essays which explore theoretical aspects of biomedical research with a clear view toward eventual biomedical implications.  Word limit: 3,000 words excluding references, figures, and tables with an abstract of 350 words or less.

    Perspectives are representative of an opinion about an area of the field or a direction of research. The length for either should not exceed 2,000 words and should be accompanied by an abstract of250 words or less.

    Literature Reviews:  Reviews of a topical area of research relevant to science, discussing the work of multiple research groups.  Word limit, 1,500 words excluding references, figures, and tables.

    Meeting Reports:  Accounts of a representative sample of talks or poster presentations at a recent conference or symposium.  1,500 word limit.  Abstract not required.

    Letters to the Editor:  A forum for presentation of preliminary clinical results, advances in technology, and case reports. In addition, letters extending, contesting, challenging, or disputing claims advanced in previous publications are encouraged and will be submitted to the original authors for comment.  Word limit:  1,200 words with no more than four references and one figure or table.

    Peer Review Process and Policy

    Manuscripts are typically reviewed by 2 or more peer reviewers in the field of study and are expected to meet the standards of academic and scientific excellence.  The initial review process usually takes between 4-10 weeks; revisions require additional time.  Each reviewer is asked to provide constructive comments to aid authors in improving their work for publication, either in BioResearch: Open Access, or elsewhere if it is rejected.  The final decision to accept or reject a paper is made by the Editor-in-Chief after the review process is complete.

    Authors are encouraged to supply the names and email addresses of 3–4 individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be included in the review process along with the reason for this request.

    Ethical Considerations in the Conduct and Reporting of Research: Protection of Human Subjects and Animals in Research*
     
    When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
     
    *This portion of BioResearch: Open Access Instructions for Authors has been quoted directly from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit www.icmje.org/ethical_6protection.html

    PRESENTATION

    Manuscripts submitted to BIORESEARCH: OPEN ACCESS will not be rejected solely on the basis of errors in sentence construction, syntax, and grammar. BIORESEARCH: OPEN ACCESS strives to communicate meritorious research from all countries, and reviews will not be compromised due to deficiencies in presentations. However, manuscripts which require substantial editing may, at the editors’ discretion, be referred to an editorial service for a fee. Please contact the Editor-in-Chief for details.

     

    PREPARATION OF MANUSCRIPTS

    Manuscripts must be double-spaced in an 8 1/2 x 11 format with margins of 1 inch on all sides and should be prepared in Microsoft Word.

    Please follow these guidelines for submitting figures:

    • Do NOT embed art files into a Word or PDF document
    • Line illustrations should be submitted at 900 dpi
    • Halftones and color should be submitted at a minimum of 300 dpi
    • Save as either TIFF or EPS files
    • Color art must be saved as CYMK - not RGB
    • Black and White art must be submitted as grayscale – not RGB
    • Excel files cannot be uploaded. It is best to avoid submitted PowerPoint files.  For directions on how to convert a Power Point slide to an acceptable format go to www.liebertpub.com/MEDIA/pdf/ppconvert.pdf

    Please name your artwork files with the first author’s last name, and figure/table number.

    Ex: Smith.Fig1; Smith.Table2; etc.

    Color Reproduction

    BioResearch: Open Access does not currently impose a charge for the cost of color reproduction.

     

    ADDITIONAL INFORMATION ABOUT ART FILES

    Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

    • All files should be scanned at 100% size
    • 300 dpi
    • Final color mode: cmyk
    • Save file as: .tif or .eps


    SEQUENCE OF SECTIONS


    The title page should contain: A) the complete title of the paper; B) the full name, full mailing address, full contact information (telephone, fax, and e-mail address), and affiliations of each author. C) a brief running title consisting of no more than 45 characters (including spaces); D) the corresponding author’s complete contact information including address and working fax number and/or e-mail address.

    Footnotes and abbreviations: List information such as prior conference presentation of the submitted material and a list of non-standard abbreviations (standard abbreviations need not be listed).

    Abstract: 250 words or less, without the use of subheadings.

    Introduction: Describe the background leading to the study and clearly state the purpose of the study or its major contribution.

    Materials and Methods: Provide sufficient information to permit both reproduction of the results by other investigators and appropriate critical evaluation of the procedures used.

    Results.

    Discussion: The results and discussion sections of short papers may be combined for more effective presentation.

    Acknowledgments: State funding sources and other assistance that were necessary for the conduct of the study.

    Author Disclosure Statement:  Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at http://www.icmje.org/index.html#conflicts for further guidance.  If no conflicts exist, the authors must state “No competing financial interests exist."

    References: Should be cited in the text and listed numerically at the end of the paper in the order of citation, as detailed in instructions below.

    Figure legends: These must be double-spaced on a separate page at the end of the manuscript.

    Tables: Number these consecutively throughout the text. Tables should be prepared in separate, individual files, and should not be included as part of the main text document

    ____________________________________________________________________


    IMPORTANT:

    Please upload individual files of all manuscript material — do NOT upload a single PDF file containing all text, figure, and table files of your paper. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.

    ____________________________________________________________________



    REFERENCES (PLEASE FOLLOW CAREFULLY)

    References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper. Authors are responsible for the accuracy of all literature citations. Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text. References should be listed numerically in the text in the order of appearance as superscripted consecutive numbers, e.g., 1,2. Where there are more than two references, the citation should appear as hyphenated numbers, e.g., 1–3. The reference section should be typed double-spaced in numerical order of citation, with the first three authors listed, followed by et al. Abbreviations of journals titles should conform to those used in Medline. The following formats must be used:


    Journal Articles 


    1.  Choi JS, Kim BS, Kim JD, et al. In vitro cartilage tissue engineering using adipose-derived extracellular matrix scaffolds seeded with adipose-derived stem cells.  Tissue Eng Part A. 2012;18:80-92.

     

    Book

    2.  Rao MS, Mohan C. Vemuri MC, Carpenter M. (eds.) Neural Development and Stem Cells, 2nd ed. Humana Press: New York, NY, 2005.

    Book Chapter

    3. Hénon P. Clinical aspects of autologous blood stem cell transplantation. Review of indications. In: Peripheral Blood Stem Cell Autografts. Wunder E, Henon P, (eds.) Springer-Verlag: Heidelberg, Germany; pp. 209–240; 1993.

     

    PERMISSIONS


    Written permission must be obtained from the publisher of the journal or book concerned for the reproduction of figures, tables, etc. from copyrighted materials.

    The publication from which the figure or table is taken must be listed in the reference list.

    A footnote of a reprinted table, or of the legend of a reprinted figure, should read, “Reprinted with permission from Jones et al.” and list the appropriate reference.

    COPYRIGHT

    Unless rejected for publication, all submissions become the property of Mary Ann Liebert, Inc., Publishers. By submitting their work for review by BioResearch: Open Access, all authors and co-authors acknowledge transfer of the copyright of their submission to Mary Ann Liebert, Inc. Such copyright shall automatically revert to the author(s) if the paper is withdrawn prior to the time when the paper is typeset for publication or if the paper is not accepted for publication. While no part of any publication may be reproduced in any form without written consent of the publisher and credit to the original material, such consent shall not unreasonably be denied. Consent can be obtained by contacting the editor-in-chief.

    REPRINTS


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

    PUBLISHER

    BioResearch Open Access is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; Fax: (914) 740–2101; Website:  www.liebertpub.com

     

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy


    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

     

    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 

     

     

     

Recommended Publications

You may be interested in the following publications:

    AIDS Research and Human Retroviruses

    AIDS Research and Human Retroviruses

    The leading journal in the field for over 25 years, providing the latest developments and research advances in HIV/AIDS and other retroviruses leading to improvements in translational medicine for optimal treatment outcomes.

    Cellular Reprogramming

    Cellular Reprogramming

    Cutting-edge techniques and the latest high-quality research on the etiology, development, and potential treatment of various diseases through reprogramming cellular mechanisms.

    Disruptive Science and Technology

    Disruptive Science and Technology

    Breakthrough, highly innovative, peer-reviewed research and discoveries that cultivate, harness, and explore how existing paradigms can be changed to improve human health, well-being, and productivity.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

    Environmental Engineering Science

    Environmental Engineering Science

    The authoritative peer-reviewed journal publishing state-of-the-art studies of innovative solutions to problems in air, water, and land contamination and waste disposal.

    Genetic Engineering & Biotechnology News

    Genetic Engineering & Biotechnology News

    The mostly widely-read publication covering tools, techniques, and technologies in the biotechnology industry.

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

    Nucleic Acid Therapeutics

    Nucleic Acid Therapeutics

    formerly Oligonucleotides

    Focuses on cutting-edge research and applications to find and examine new approaches using nucleic acids in therapeutics including oligonucleotides, gene modification, aptamers, RNA nanoparticles, ribozymes, and more.

    Diabetes Technology & Therapeutics

    Diabetes Technology & Therapeutics

    The only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes.

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

    Tissue Engineering, Parts A, B, & C

    Tissue Engineering, Parts A, B, & C

    The preeminent, biomedical journal bringing together the principles of engineering and life sciences to advance the field with cutting-edge research and applications on all aspects of tissue growth and regeneration.

    Viral Immunology

    Viral Immunology

    The only journal reporting on all aspects of the rapidly growing field of viral immunology, with comprehensive coverage of immune responses to viral infections from basic mechanisms to clinical applications.

    Zebrafish

    Zebrafish

    Solely focused on disseminating the latest cutting-edge advances in the zebrafish as a model organism for the study of vertebrate development, with attention to other aquarium species including medaka, Fugu, and Xiphophorus.

    Vector-Borne and Zoonotic Diseases

    Vector-Borne and Zoonotic Diseases

    The first authoritative peer-reviewed journal providing basic and applied research on diseases transmitted to humans by invertebrate vectors or non-human vertebrates.

    Rejuvenation Research

    Rejuvenation Research

    Key explorations and cutting-edge advancements on the molecular and cellular mechanisms that may ultimately contribute to slowing or reversing the aging process.

Browse All Publications »